GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Atrion Corp (NAS:ATRI) » Definitions » Risk Assessment

Atrion (Atrion) Risk Assessment


View and export this data going back to 1972. Start your Free Trial

What is Atrion Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Atrion is: Low Risk: Strong fundamentals, worth long-term holding.


Competitive Comparison of Atrion's Risk Assessment

For the Medical Instruments & Supplies subindustry, Atrion's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atrion's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Atrion's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Atrion's Risk Assessment falls into.



Atrion  (NAS:ATRI) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.


Atrion Risk Assessment Related Terms

Thank you for viewing the detailed overview of Atrion's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.


Atrion (Atrion) Business Description

Traded in Other Exchanges
N/A
Address
One Allentown Parkway, Allen, TX, USA, 75002-4211
Atrion Corp develops and manufactures products for medical applications. Its fluid-delivery products contribute the largest proportion of revenue and include valves that can hold and release controlled amounts of fluids or gases and are often used in anesthesia and oncology applications. Atrion's cardiovascular products include the MPS2 Myocardial Protection System, which delivers fluids and medications, mixes drugs, and controls temperature and pressure during open-heart surgery. The cardiovascular business also sells cardiac-surgery vacuum relief valves, inflation devices, and other products used in heart surgery. The firm's ophthalmic products include medical devices that disinfect contact lenses. Atrion generates the majority of revenue in the United States.
Executives
Preston G Athey director ONE ALLENTOWN PKWY, ALLEN TX 75002
David A Battat officer: President & CEO 2700 HALKEY-ROBERTS PLACE NORTH, ST. PETERSBURG FL 33716-4103
Jeannette Bankes director ONE ALLENTOWN PARKWAY, ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Morgan Hugh J Jr director
Ronald Nicholas Spaulding director ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Cindy Ferguson officer: Officer/ CFO ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Jeffery Strickland officer: Vice President & CFO
Emile A Battat director, officer: Chairman ONE ALLENTOWN PARKWAY, ALLEN TX 75002
Maria Sainz director C/O ORTHOFIX INTERNATIONAL N. V., 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Stupp John P Jr director STUPP JOHN P JR, #18 ST. ANDREWS DR., ST LOUIS MO 63124
Roger F Stebbing director
Ronald N Spaulding director C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Richard O Jacobson director ONE ALLENTOWN PARKWAY, C/O ATRION, ALLEN TX 75002
Maley John H P director 6 ROCK CREST LANE, SIGNAL MOUNTAIN TN 37377
Margaret Maxwell Zagel director C/O TELLABS OPERATIONS INC, 4951 INDIANA AVE, LISLE IL 60532

Atrion (Atrion) Headlines

From GuruFocus

Atrion Reports First Quarter 2022 Results

By GuruFocusNews GuruFocusNews 05-19-2022

Atrion Corporation Declares Quarterly Cash Dividend

By Value_Insider Value_Insider 11-14-2022

Atrion Reports First Quarter 2022 Results

By GuruFocusNews GuruFocusNews 05-09-2022

Atrion Corporation Declares Quarterly Cash Dividend

By sperokesalga sperokesalga 02-27-2023

Atrion Reports First Quarter 2022 Results

By GuruFocusNews GuruFocusNews 06-08-2022

Atrion Corporation Announces Election of New Director

By Marketwired Marketwired 08-30-2021

Atrion Corporation Increases Quarterly Cash Dividend by 11%

By Marketwired Marketwired 08-30-2021

Atrion Corporation Declares Quarterly Cash Dividend

By GuruFocusNews GuruFocusNews 06-03-2022